Program
leronlimab
Also written as “PRO 140”, “Leronlimab (700mg)” and “350 mg leronlimab”.
Its studies are mostly in Acquired Immunodeficiency Syndrome · COVID-19 · HIV Infections · Colorectal Neoplasms · Triple Negative Breast Neoplasms, led by CytoDyn.
Drug pageLeronlimab: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CytoDyn | 201 open or running | phase 3since Jun 24, 2015 | May 10, 2005 | Jan 2028phase 2 · NCT06699836 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 6 studies since May 10, 2005.
- Jun 24, 2015Phase 3 study in HIVNCT02483078 · 52 enrolled · United States, Puerto Rico
- Mar 29, 2016Phase 2 study in Graft vs Host DiseaseNCT02737306 · 11 enrolled · United States
- Jul 13, 2016Phase 3 study in HIVNCT02859961 · 562 enrolled · United States
- Nov 17, 2016Phase 3 study in Acquired Immunodeficiency SyndromeNCT02990858 · 43 enrolled
- Dec 9, 2017Named leronlimabINNProposed as its International Nonproprietary Name in WHO's List 118 · before, PRO 140
- Feb 5, 2019Phase 2 study in Triple Negative Breast NeoplasmsNCT03838367 · 10 enrolled · United States
- Apr 2, 2019Phase 3 study in HIV-1-infectionNCT03902522 · 6 enrolled · United States
- Nov 18, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT04521114 · 87 enrolled · United States
- Mar 31, 2020Phase 2 study in COVID-19NCT04343651 · 86 enrolled · United States
- Apr 13, 2020Phase 2 study in COVID-19NCT04347239 · 484 enrolled · United States
- Jun 10, 2020Phase 2 study in Solid Tumor, AdultNCT04504942 · 16 enrolled · United States
- Dec 14, 2020Phase 2 study in COVID-19NCT04678830 · 56 enrolled · United States
- Jan 13, 2022Phase 3 study in HIV-1-infectionNCT05271370 · 56 enrolled · United States
- Feb 7, 2023Phase 2 study in Neoplasm MetastasisNCT05730673
- Nov 19, 2024Phase 2 study in Colorectal NeoplasmsNCT06699836 · 66 enrolled · United States
Ahead
- Jan 2028Primary completion: phase 2 study in Colorectal NeoplasmsNCT06699836
TargetBeta
“A humanized immunoglobulin (Ig) G4 monoclonal antibody against CC chemokine receptor 5 (CCR5; CD195), ”NCIt, by rule
“C-C chemokine receptor type 5 antagonist”ChEMBL 37, by rule
Other programs on CCR5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Maravirocrule | GlaxoSmithKline | phase 4 | 26 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06699836Colorectal Neoplasms · United States | 2 | Active, not recruiting | Jan 2028 | 66 |
| NCT05730673Neoplasm Metastasis | 2 | Withdrawn | May 27, 2023 | 0 |
| NCT05271370HIV-1-infection · United States | 3 | Terminated | Jun 20, 2022 | 56 |
| NCT04678830COVID-19 · United States | 2 | Completed | Jun 5, 2021 | 56 |
| NCT04504942Solid Tumor, Adult · United States | 2 | Completed | Nov 7, 2021 | 16 |
| NCT04347239COVID-19 · United States | 2 | Completed | Oct 24, 2021 | 484 |
| NCT04343651COVID-19 · United States | 2 | Completed | Jul 21, 2020 | 86 |
| NCT04521114Non-alcoholic Fatty Liver Disease · United States | 2 | Completed | Dec 29, 2021 | 87 |
| NCT03902522HIV-1-infection · United States | 3 | Completed | May 18, 2020 | 6 |
| NCT03838367Triple Negative Breast Neoplasms · United States | 2 | Terminated | Jul 15, 2022 | 10 |
| NCT02990858Acquired Immunodeficiency Syndrome | 3 | Terminated | Jun 2022 | 43 |
| NCT02859961HIV · United States | 3 | Completed | Sep 16, 2020 | 562 |
| NCT02737306Graft vs Host Disease · United States | 2 | Terminated | Apr 14, 2021 | 11 |
| NCT02483078HIV · United States, Puerto Rico | 3 | Completed | Feb 2018 | 52 |
| NCT02355184Acquired Immunodeficiency Syndrome · United States | 2 | Terminated | Jun 2022 | 20 |
| NCT02175680Acquired Immunodeficiency Syndrome · United States | 2 | Completed | Feb 2, 2015 | 43 |
| NCT01272258HIV · United States | 2 | Withdrawn | Jan 2017 | 0 |
| NCT00642707HIV Infections · United States | 2 | Completed | Nov 2008 | 44 |
| NCT00613379HIV Infections · United States | 2 | Completed | Aug 2008 | 30 |
| NCT00110591HIV Infections · United States | 1 | Completed | Nov 7, 2005 | 20 |
How it is read
Names in the registry
- “PRO 140”, 9 entries
- “Leronlimab (700mg)”, 3 entries
- “350 mg leronlimab”, 2 entries
- “700 mg leronlimab”, 2 entries
- “PRO 140 (350 mg)”, 1 entry
Conditions, from the studies’ own filings
- Acquired Immunodeficiency Syndrome, 3 studies
- COVID-19, 3 studies
- HIV Infections, 3 studies
- Colorectal Neoplasms, 1 study
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.